Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel treatment method

A disease and effective dose technology, applied in the field of compositions for treating lung diseases, can solve problems such as identification of difficult disease therapeutic agents

Inactive Publication Date: 2004-12-01
GLAXO GROUP LTD
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Identification of novel therapeutic agents for lung disease is difficult due to the variety of mediators responsible for its development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 - Phosphodiesterase and Cyclopentyloxymethoxyphenylpyrrolidone Binding Assay

Embodiment 1A

[0047] Determination of PDE4 and hrPDE (human recombinant PDE4) in isolated human monocytes, mainly in the form of low affinity. Therefore, the activity of test compounds against low affinity forms of PDE4 can be assessed using standard PDE4 catalytic activity assays using 1 μM [ 3 H] cAMP as a substrate (Torphy et al., J. of Biol. Chem., Vol. 267, No. 3 pp1798-1804, 1992).

[0048] Use rat brain high-speed supernatant as a protein source. preparation[ 3 The enantiomer of H]-cyclopentyloxymethoxyphenylpyrrolidone with a specific activity of 25.6Ci / mmol. Modify the standard assay conditions according to the published method, which is equivalent to the PDE assay conditions, except that the final cAMP: 50mM Tris-HCl (pH7.5), 5mM MgCl 2 , lnM[ 3 H]-cyclopentyloxymethoxyphenylpyrrolidone (Torphy et al., J. of Biol. Chem., Vol. 267, No. 3 pp1798-1804, 1992). The measurement was performed at 30°C for 1 hour. The reaction was terminated and bound and free ligand was separated us...

Embodiment 1B

[0050] Measurement of phosphodiesterase activity

[0051] Using as described by the supplier (Amersham Life Sciences) [ 3 H] cAMP scintillation approximation assay (SPA) or [ 3 H] cGMP SPA enzyme assay to measure PDE activity. Reactions were carried out in 96-well plates at room temperature in 0.1 ml reaction buffer containing (final concentration): 50 mM Tris-HCl, pH 7.5, 8.3 mM MgCl 2 , 1.7mM EGTA, [ 3 H] cAMP or [ 3 H] cGMP (approximately 2000 dpm / pmol), enzyme and various concentrations of inhibitors. The assay was allowed to proceed for 1 hour and was terminated by the addition of 50 [mu]l SPA yttrium silicate beads in the presence of zinc sulfate. Shake the plate and let stand at room temperature for 20 minutes. The generation of radiolabeled products was assessed by means of scintillation spectrometry. Use 0.05 μM [ 3 H] cAMP to assess the activity of PDE3 and PDE7, using 1 μM [ 3 H]cAMP was used as a substrate to assess the activity of PDE4. Use 1 μM [ 3 H] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods of treating pulmonary disorders, such as obstructive pulmonary disease or asthma, by administering a phosphodiesterase 4 inhibitor in combination with an anticholinergic agent.

Description

field of invention [0001] The present invention relates to compositions and methods for preventing or reducing the onset of, or treating or reducing the severity of, pulmonary disease symptoms. In particular, the present invention relates to the administration of a PDE4 inhibitor and an anticholinergic agent, specifically M 1 , M 2 , M 1 / M 2 or M 3 Receptor antagonists, compositions and methods for treating lung diseases. Background of the invention [0002] Because of the variety of mediators responsible for the development of lung disease, the identification of novel therapeutic agents for this disease is difficult. Thus, it seems unlikely that eliminating the effects of a single mediator would have a substantial effect on all other components of a given lung disease. An alternative to the "mediator approach" is to modulate the activity of cells responsible for the pathophysiology of the disease. This approach as set forth in the present invention employs two modul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/192A61K31/275A61K31/439A61K31/46A61K45/06A61K45/08A61P11/00A61P11/06A61P43/00
CPCA61K45/06A61K31/192A61K31/46A61P11/00A61P11/06A61P43/00A61K2300/00
Inventor 理查德·G·诺尔斯彼得·沃德
Owner GLAXO GROUP LTD